PSP Research LLC Acquires Shares of 11,678 Xenon Pharmaceuticals Inc. $XENE

PSP Research LLC acquired a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,678 shares of the biopharmaceutical company’s stock, valued at approximately $523,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Wellington Management Group LLP grew its holdings in Xenon Pharmaceuticals by 66.0% during the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after purchasing an additional 1,435,096 shares during the period. Commodore Capital LP lifted its position in shares of Xenon Pharmaceuticals by 30.1% during the second quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock worth $94,682,000 after acquiring an additional 700,000 shares in the last quarter. Vestal Point Capital LP lifted its position in shares of Xenon Pharmaceuticals by 53.8% during the second quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $62,600,000 after acquiring an additional 700,000 shares in the last quarter. Holocene Advisors LP lifted its position in shares of Xenon Pharmaceuticals by 9.2% during the third quarter. Holocene Advisors LP now owns 1,976,553 shares of the biopharmaceutical company’s stock worth $79,359,000 after acquiring an additional 167,078 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its position in shares of Xenon Pharmaceuticals by 8.9% during the third quarter. Alliancebernstein L.P. now owns 1,654,417 shares of the biopharmaceutical company’s stock worth $66,425,000 after acquiring an additional 135,890 shares in the last quarter. 95.45% of the stock is owned by institutional investors.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, insider Andrea Difabio sold 1,342 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $55.23, for a total transaction of $74,118.66. Following the sale, the insider owned 7,301 shares in the company, valued at $403,234.23. This trade represents a 15.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Christopher John Kenney sold 1,410 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $55.23, for a total value of $77,874.30. Following the sale, the insider owned 7,069 shares in the company, valued at $390,420.87. The trade was a 16.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 296,707 shares of company stock worth $17,845,365 over the last 90 days. Corporate insiders own 4.07% of the company’s stock.

Xenon Pharmaceuticals Stock Performance

Shares of XENE stock opened at $54.05 on Wednesday. Xenon Pharmaceuticals Inc. has a 52-week low of $28.19 and a 52-week high of $63.95. The company has a market capitalization of $5.23 billion, a PE ratio of -11.50 and a beta of 0.65. The business’s fifty day moving average is $56.54 and its 200 day moving average is $47.35.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same period in the previous year, the company posted ($0.83) earnings per share. On average, sell-side analysts forecast that Xenon Pharmaceuticals Inc. will post -4.88 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on XENE shares. Royal Bank Of Canada increased their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Jefferies Financial Group set a $100.00 target price on Xenon Pharmaceuticals in a research report on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Wednesday, April 8th. Deutsche Bank Aktiengesellschaft increased their target price on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Finally, Stifel Nicolaus set a $66.00 target price on Xenon Pharmaceuticals in a research report on Tuesday, February 10th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $77.07.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.